Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Dallas Morning News on MSN21h
FDA adds new warning to weight loss drugs including WegovyThe U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that ...
Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...
The NHS rollout of appetite suppressing injections has been thrown into doubt after what is believed to be the first confirmed death linked to the controversial drugs ...
Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on ...
The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...
"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback